| 1 |
Wang J, Chai J, Sun L, et al. The sputum microbiome associated with different sub-types of AECOPD in a Chinese cohort[J]. BMC Infect Dis, 2020, 20(1): 610.
|
| 2 |
Pei Z, Sun Y, Wang S, et al. Estimating mortality among in patients with acute exacerbation of chronic obstructive pulmonary disease using registry data[J]. NPJ Prim Care Respir Med, 2020, 30(1): 28.
|
| 3 |
Ernst P, Dahl M, Chateau D, et al. Canadian network for observational drug effect studies (CNODES) Investigators. Comparative effectiveness of fluoroquinolone antibiotic use in uncomplicated acute exacerbations of COPD: a multi-cohort study[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14(1): 2939-2946.
|
| 4 |
Ra SW, Kwon YS, Yoon SH, et al. Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(4): 1424-1432.
|
| 5 |
Montón C, Prina E, Pomares X, et al. Nebulized colistin and continuous cyclic azithromycin in severe COPD patients with chronic bronchial infection due to Pseudomonas aeruginosa: a retrospective cohort study[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14(1): 2365-2373.
|
| 6 |
慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J]. 国际呼吸杂志，2017, 37(14): 1041-1057.
|
| 7 |
Sperrin M, Webb DJ, Patel P, et al. Chronic obstructive pulmonary disease exacerbation episodes derived from electronic health record data validated using clinical trial data[J]. Pharmacoepidemiol Drug Saf, 2019, 28(10): 1369-1376.
|
| 8 |
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
|
| 9 |
Spencer L. Pulmonary rehabilitation for patients with acute chronic obstructive pulmonary disease exacerbations: is the evidence strengthening? [J]. Curr Opin Pulm Med, 2018, 24(2): 147-151.
|
| 10 |
Wang H, Anthony D, Selemidis S, et al. Resolving viral-induced secondary bacterial infection in COPD: a concise review[J]. Front Immunol, 2018, 9(1): 2345.
|
| 11 |
Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
|
| 12 |
Su YC, Jalalvand F, Thegerström J, et al. The interplay between immune response and bacterial infection in COPD: focus upon non-typeable Haemophilus influenzae[J]. Front Immunol, 2018, 9(1): 2530.
|
| 13 |
Messous S, Elargoubi A, Pillet S, et al. Bacterial and viral infection in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease: implication for antimicrobial management and clinical outcome[J]. COPD, 2021, 18(1): 53-61.
|
| 14 |
Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis[J]. Eur Respir Rev, 2017, 26(143): 160073.
|
| 15 |
Stolz D, Papakonstantinou E, Grize L, et al. Time-course of upper respiratory tract viral infection and COPD exacerbation[J]. Eur Respir J, 2019, 54(4): 1900407.
|
| 16 |
Yin T, Zhu Z, Mei Z, et al. Analysis of viral infection and biomarkers in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(3): 1228-1239.
|
| 17 |
Alotaibi NM, Chen V, Hollander Z, et al. Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14(1): 311-319.
|
| 18 |
Santoro A, Tomino C, Prinzi G, et al. Microbiome in chronic obstructive pulmonary disease: role of natural products against microbial pathogens[J]. Curr Med Chem, 2020, 27(18): 2931-2948.
|
| 19 |
Eklöf J, Sørensen R, Ingebrigtsen TS, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22？053 patients[J]. Clin Microbiol Infect, 2020, 26(2): 227-234.
|
| 20 |
Mulpuru S, Li L, Ye L, et al. Serious outcomes surveillance (SOS) network of the Canadian immunization research network (CIRN). Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD[J]. Chest, 2019, 155(1): 69-78.
|
| 21 |
Menzel M, Ramu S, Calvén J, et al. Oxidative stress attenuates TLR3 responsiveness and impairs anti-viral mechanisms in bronchial rpithelial cells from COPD and asthma patients[J]. Front Immunol, 2019, 10(1): 2765.
|
| 22 |
Choi J, Oh JY, Lee YS, et al. Bacterial and viral identification rate in acute exacerbation of chronic obstructive pulmonary disease in Korea[J]. Yonsei Med J, 2019, 60(2): 216-222.
|
| 23 |
Choi J, Oh JY, Lee YS, et al. Pseudomonas aeruginosa infection increases the readmission rate of COPD patients[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13(1): 3077-3083.
|
| 24 |
Jafarinejad H, Moghoofei M, Mostafaei S, et al. Worldwide prevalence of viral infection in AECOPD patients: A meta-analysis[J]. Microb Pathog, 2017, 113(1): 190-196.
|
| 25 |
Niespodziana K, Napora K, Cabauatan C, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections[J]. FASEB J, 2012, 26(3): 1001-1008.
|
| 26 |
Chen Y, Kumar RK, Thomas PS, et al. Th1/17-Biased inflammatory environment associated with COPD alters the response of airway epithelial cells to viral and bacterial stimuli[J]. Mediators Inflamm, 2019, 20(19): 7281462.
|